Breaking Down the Barriers to Optimal Diabetes Outcomes: Considerations for GLP-1 Agonists

Breaking Down the Barriers to Optimal Diabetes Outcomes:

Considerations for GLP-1 Agonists

A series of Live Grand Rounds Presentations and an on-demand CME-certified Webcourse.

Welcome to "Breaking Down the Barriers to Optimal Diabetes Outcomes: Considerations for GLP-1 Agonists." This CME-certified initiative is intended for internists, PCPs, nurses, hospital-based pharmacists, NPs, and PAs involved in the management of patients with T2DM. A series of live CME-certified in-hospital presentations will be held at locations nationwide and an online CME-certified webcourse will be available in December 2014.

Program Overview/Statement of Need:

The most recent State of Health Care Quality Report, published by the National Committee for Quality Assurance (NCQA), indicated that only 43.2% of patients with diabetes had good HbA1c control (<7%), while 61.3% had an HbA1c of <8% and 28.5% had poor control (HbA1c >9%). Additional data show that many patients who reach their glycemic goal do not maintain it. Patients must become "partners in care," but more direction is needed to help clinicians successfully engage their patients.

This case-based presentation will guide internists, PCPs, nurses, hospital-based pharmacists, NPs, and PAs through the practical application of up-to-date information in T2DM management and best practices in patient engagement. Clinicians will gain an improved understanding of the place of GLP-1 agonists in the treatment armamentarium; will be better able to differentiate the GLP-1 agonists currently available, including safety and efficacy profiles and injection delivery methods; and will be prepared to involve their patients in proactive participation through each step of the decision-making process to improve patient adherence and outcomes.

Educational Objectives:

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Describe the relationships between glycemia and diabetes complications
  • Consider the HbA1c-lowering properties of GLP-1 agonists with their impacts on T2DM pathophysiology, CV risk factors, and hypoglycemic risk when individualizing treatment strategies for diabetic patients to reach target goals
  • Develop strategies to attain glycemic control throughout the life cycle of T2DM
  • Promote a collaborative approach to T2DM management, empowering the patient through individualized patient education to address and break down barriers for optimal outcomes, including adherence and injection-related barriers

Accreditation Statements:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation:

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.